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Imaging for Infected
Cardiac Implantable
Electronic Devices
A New Trick for Your Pet*
Jeffrey Brinker, MD
Baltimore, Maryland
Cardiac implantable electronic devices (CIEDs), having
been shown capable of improving the quality as well as
duration of life, are playing an increasingly important role in
the management of patients with disorders of heart rhythm
and/or function. Over the last decade there has been a
remarkable increase in CIED utilization; in the United
States alone 235,567 new and 101,042 replacement pace-
makers and 133,262 new and 73,217 replacement implant-
able cardioverter-defibrillators (ICD) were implanted in
2009 (1). Much of this growth has been driven by the
broadened utilization of the ICD, which now accounts for
over a third of all CIEDs being placed. As the indications
for CIEDs have expanded, the population in which they are
being implanted has become older and afflicted with a
higher prevalence of comorbidities (2). This would appear
to underlie observations that the increased rate of device
implantation has been accompanied by an even greater
increase in the rate of CIED infection (3). Thus, from 2004
to 2008 the rate of CIED infection increased from 1.5% to
2.4% (4). Infection of these devices carries with it significant
risk of death, considerable morbidity, and the certainty of
expense.
See page 1616
The CIED system most frequently consists of intravas-
cular (leads) and subcutaneous (generator) components
although sometimes leads are placed on the epicardial
surface of the heart or, more rarely, subcutaneously, while
the generators may be positioned below a muscle. Either of
the components, placed at any location, may be the site of
initiation and/or presentation of infection. Most often
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paper to disclose.infection presents as a process localized to the generator
pocket. It is thought to result from microbes introduced at
the time of device placement or from a subsequent breach of
the skin. This assumption is supported by the temporal
relationship of pocket creation or revision with the onset of
infection as well as the finding of typical skin flora in the
pocket at the time of implant (5) and in asymptomatic
patients receiving generator exchange (6). About 40% of
infections present with systemic symptoms and bacteremia
often due to seeding of leads from a source other than the
pacemaker pocket (e.g., intravenous access line, hemodial-
ysis fistula). Regardless of initial presentation, it is not
unusual to find that both leads and generator culture are
positive for the offending organism. While a wide variety of
bacteria and fungi have been associated with CIED infec-
tions, those usually responsible are coagulase-negative
Staphylococcus species, S. aureus, and Enterococcus (7). These
rganisms, in addition to exhibiting an increasing preva-
ence and spectra of antibiotic resistance, have surface
omponents that facilitate attachments to tissue and foreign
aterial. Once attached they may protect themselves from
ost defenses and antibiotics by producing biofilm and/or
esiding within or under endothelium (7,8). Thus, while
IED infections may be suppressible by antibiotics, they are
enerally considered incurable by such therapy alone. Thus,
omplete removal of all hardware (including prior aban-
oned devices) is considered necessary in almost all situa-
ions in which any part of the system is infected (8).
Removal of a recently implanted CIED is usually
traightforward and safe; however, chronically implanted
ead systems, whether infected or not, may be difficult to
xtract because of fibrous intravascular and intracardiac
dhesions. Extraction in such cases is accompanied by major
omplication in up to 2% of procedures, including death in
bout 0.3%. The non–procedure-related in-hospital death
ate of infected patients, influenced by the infection itself
nd/or comorbidity, may be as high as 5%, with a 1-year
ortality of 17% (9). Death is more common in patients
ith endovascular infection and appears related to a delay in
ardware removal despite antibiotic therapy (10). While as
any as 40% of patients may not need a replacement CIED
fter extraction and infection control (11), most patients do
ventually receive such. Device-dependent patients often
emain in the hospital until this is accomplished, which may
e in excess of 2 weeks in those having endovascular
nfection. Recurrent infection after removal and subsequent
IED replacement is not frequent but has been attributed
o retained hardware, seeding from a persistent infection at
nother site, or premature replacement of a CEID. The
n-hospital charges for a CIED infection are in excess of
140,000 (4).
Delay from presentation to hardware removal stems from
ailure to recognize the presence of an infection or mistaken
ttribution of an infection to another source is thought to
ncrease the risk of adverse outcome for those with CIED
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May 1, 2012:1626–8 Imaging for Infected CIEDsinfection. A high index of suspicion is essential for early
diagnosis and should trigger blood culture, antibiotic ther-
apy, and, in those with bacteremia or who have been on
antibiotics prior to a negative culture, transesophageal echo-
cardiography (TEE) (8). Unfortunately the diagnosis may
still remain unclear because the results of such testing are
neither absolutely specific nor sensitive for device infection.
Physicians and surgeons with interest and expertise in the
removal of chronically implanted CIEDs (“extractionists”),
in consultation with infectious disease specialists, are the
final arbiters of whether the system should be explanted.
Their decision making would be facilitated by the availabil-
ity of additional tools of demonstrably high diagnostic
accuracy. The potential value of radionuclide imaging in the
diagnosis of CIED infection has been suggested in a
number of case reports and small series of patients. Agents
such as 67gallium (12), 111indium-labeled leukocytes (13),
nd 99mtechnetium-labeled leukocytes (14) have demon-
trated uptake in both the device pocket and along the
ubcutaneous and intravascular course of leads in patients
ith infection.
There is increasing evidence that fluorodeoxyglucose
arked by fluorine-18 (18F-FDG) positron emission tomog-
raphy (PET) coregistered with computed tomography (CT) is
useful for the detection and localization of infection (15–17)
including infective endocarditis (18). A number of case
reports confirm the potential applicability for this technique
in suspected CIED infection (19–21) with the ability to
localize infection on the device as well as its spread to near
(heart valves) and distant metastatic sites, which can be of
great practical value. The high diagnostic accuracy and cost
effectiveness of 18F-FDG-PET in the evaluation of fever of
nknown etiology (22) and blood stream infections (23)
uggest that this modality may be helpful early in the
orkup of these disorders. Ploux et al. (24) explored the
tility of 18F-FDG-PET in 10 CIED patients presenting
with fever of unknown origin despite evaluation that in-
cluded TEE. Six had tracer uptake on a lead and had
hardware removal while 4 had no uptake and were treated
conservatively. Infection was confirmed by culture of ex-
tracted leads in all 6 of the former while none of the latter
had recurrence during a 13-month follow-up. Forty addi-
tional CIED patients undergoing 18F-FDG-PET/CT for
uspected malignancy formed a control group in which 3
ad a false positive scan for CIED infection. Similarly,
ensimhon et al. (25) evaluated 21 patients suspected of
aving device infection and 14 “control” CIED patients
eing evaluated by 18F-FDG-PET for oncologic purposes.
f the former the sensitivity and specificity for detecting
ocket infection were both 100%; for lead infection, speci-
city was also 100%, however, the sensitivity was only 60%.
verall, 18F-FDG-PET/CT performed well in the detec-
ion of CIED infection per se, with a sensitivity of 80% and
pecificity of 100%. In 4 patients having device infection
18F-FDG-PET/CT also demonstrated 2 lung infections,
infection of a right ventricular to pulmonary artery conduit, nand an infection of the tarsal bone. None of the control
patients were positive for CIED uptake. The authors
suggest that these results might have changed management
in 28% of patients suspected of having CIED infections.
In this issue of the Journal, Sarrazin et al. (26) make
additional important contributions regarding the utility of
18F-FDG-PET/CT for suspected CIED infection. They
provide evidence that inflammation accompanying acute
pocket surgery does not result in false positive imaging, thus
extending the applicability of this technique to suspected
early device infection. The authors also demonstrate the
ability to distinguish deep pocket infection, which implies
device infection and the necessity for device removal, from
superficial infection, which can be treated with antibiotics
alone. Interestingly they identified 4 patients (3 of whom
were bacteremic) with negative scans, despite TEE-defined
lead and/or valve “vegetations,” who were treated with
antibiotics only and remained free of recurrence over ex-
tended follow-up. The authors conclude that incorporation
of 18F-FDG-PET findings in the clinical decision making
revented the need for device removal in 6 of the 42 patients
ithout late sequelae.
Like other imaging options including TEE, 18F-FDG-
PET does not identify infection per se; rather, it localizes in
metabolically active cells be they malignant growths or
leukocytes responding to inflammation or infection. It is not
clear, then, whether this modality can be relied upon in the
presence of marked leukopenia, although some recent data
suggests that it might (27). Similarly, suppression of infec-
tion by a prolonged course of antibiotics prior to 18F-FDG-
PET scanning may result in false negative imaging. Because
imaging depends on the uptake of tagged glucose, the
presence of hyperglycemia may interfere with this process
and also be a cause of a false negative study. False positive
scans may occur as well; Sarrazin et al. (26) attributed false
positive pocket uptake in one patient to a Dacron pouch
used to contain the generator. Further study is necessary to
determine whether other additions to the pocket, such as an
antimicrobial envelope used preferentially in patients at
increased risk of pocket infection, would produce a similar
situation. Clot may also exhibit 18F-FDG-PET uptake (28)
nd, as thrombus in the central venous system is not
ncommon after lead placement, it may be difficult to
ifferentiate infection on the lead traversing the vein from
lot.
Should 18F-FDG-PET be part of the routine evaluation
f CIED infection? The evidence thus far is encouraging,
ut wider experience is needed before such a recommenda-
ion can be made. The scan is relatively expensive (at least 3
imes that of a TEE at my institution) and it exposes the
atient to radiation, which admittedly is modest considering
he importance of establishing a diagnosis. While its use at
his time is justified in diagnostic dilemmas, a better
ppreciation of the incidence of false-negative and false-
ositive scans as well as the possible causes of such would be
ecessary before it is widely embraced. Additionally, while
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Imaging for Infected CIEDs May 1, 2012:1626–818F-FDG-PET/CT is generally available, it is not clear
whether additional interpretive skills to appreciate subtleties of
CIED infection are required for optimal diagnostic accu-
racy. Favorable experience derived from prospective em-
ployment of the diagnostic algorithms proposed by Sarrazin
et al. (26) would go far in determining whether this PET
will indeed become the extractionists’ best friend.
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